Molecular glue-focused biotech f5 Therapeutics has failed to stick around for the long haul, shuttering after six years, according to an announcement from the company’s CEO on LinkedIn. “The past few ...

Less than a week after Roche pledged a hefty investment in the South Korean biopharma industry, Eli Lilly is following suit with a $500 million, five-year pact of its own. Like Roche, Lilly has signed ...

Voyager Therapeutics has hit pause on a preclinical Alzheimer’s disease program just eight months after unveiling the asset. The neurology biotech announced back in July 2025 that it was adding a new ...

Wisconsin Sen. Ron Johnson is asking to see several of the complete response letters that have been delivered of late and also told Bloomberg that he may call on top FDA leaders to testify before the ...

Uğur Şahin, M.D., who is currently the CEO of BioNTech, and his wife Özlem Türeci, M.D., who is chief medical officer, founded mRNA-focused BioNTech in 2008. The company rose to prominence and ...

Ascletis Pharma has posted phase 2 data on its ultra-long-acting GLP-1 receptor analog, generating early evidence that the formulation may support quarterly dosing as a maintenance therapy. Eli ...

Vertex reported a phase 3 win for its kidney disease prospect povetacicept, meeting analyst expectations and firing the starting gun on a race to the FDA that could result in an accelerated approval ...

San Francisco venture capital firm Breakout Ventures announced the close of a $114 million fund to support founder-led companies working at the nexus of science and artificial intelligence. | San ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...

AbbVie has unveiled the first data from its $350 million obesity bet, with the amylin analog demonstrating weight loss of close to 10% after 12 weeks in one dose cohort.

Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival (PFS) ...

Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. | Pfizer is ramping up plans for ...